Novavax Reports Significant Vaccine Development Progress
Novavax, Inc. recently announced that CPL Biologics (CPLB), its joint venture in
Cadila is one of the largest private pharmaceutical companies in
Among the joint venture’s recent achievements is the development of a rabies vaccine candidate engineered by Novavax, which has shown great promise in preclinical testing. Rabies remains a significant public health hazard in
In addition, CPLB has made rapid progress with the validation of its state-of-the-art manufacturing facility in
CPLB is also now pursuing early development of undisclosed new vaccine candidates to prevent other diseases. The targets of these vaccine candidates will be identified as they progress into preclinical and clinical studies.
“CPLB has made great progress this year with its state-of-the-art manufacturing facility and vaccine pipeline. It continues to demonstrate the power of combining our technology with world-class research, clinical development, and manufacturing expertise to develop potential in-border vaccine solutions,” said Stanley Erck, President and CEO of Novavax. “I am particularly excited about the team’s accelerated vaccine development efforts this year and the approval by the RCGM to initiate the rabies toxicology studies, which is an important milestone. In addition to sharing directly in any success from CPLB’s efforts to commercialize vaccine products in
“Our joint venture with Novavax is progressing well and remains on track to begin clinical testing of two new vaccine candidates,” added Indravadan A. Modi, Chairman of Cadila Pharmaceuticals Ltd. “In addition, we have continued to add talented new scientific and manufacturing staff as we prepare for the launch of our production facility and expand preclinical testing of new vaccine candidates for undisclosed targets.”
Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea.
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in
The company also participates in public-private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Throughout the past decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple INDs cleared by USFDA. The company has state-of-the-art manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in
Total Page Views: 1320